IMUGENE LIMITED — Capital/Financing Update 2018

Jul 5, 2018

==> picture [175 x 57] intentionally omitted <==

6[th] July 2018

ASX Announcement Rights Issue Results & Shortfall Notification

Imugene Limited ( Company ) is pleased to announce the results of the fully underwritten 1 for 9.5 nonrenounceable pro rata rights issue ( Rights Issue ) offer to raise approximately $8.1 million (before the exercise of any New Options).

The Company refers to its Rights Issue as announced on 7 June 2018. The following notice is given in accordance with Appendix 7A of the ASX Listing Rules.

Pursuant to the Rights Issue the Company advises that it has received applications from Australian and New Zealand shareholders for 139,713,059 shares at $0.027 per share raising $3,772,257.69. All eligible Directors, being Australian residents, and all senior management have participated in the Rights Issue. The resulting shortfall from the Rights Issue is 160,803,118 shares, which the Company will now allocate to institutional investors including Private Portfolio Managers and CVC in accordance with the underwriting arrangements for the Rights Issue.

The issue of shares and attaching options pursuant to the Rights Issue and resulting shortfall is anticipated to be completed on 11 July 2018, following the general meeting of the Company to be held on 9 July 2018 as announced by the Company on 7 June 2018.

The Company’s Chief Executive Officer & Managing Director Leslie Chong, said, “We are delighted to have the ongoing confidence and support of our existing shareholders, institutional investors, management and Directors of our Company”.

==> picture [66 x 50] intentionally omitted <==

Phillip Hains Company Secretary

IMUGENE LIMITED ACN 009 179 551 Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com